Leap Therapeutics
Leap Therapeutics
LPTX
NASDAQ
2.90
USD
4.32%
About
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling.
DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501.
FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 107.2K |
| Three Month Average Volume | 2.6M |
| High Low | |
| Fifty-Two Week High | 5 USD |
| Fifty-Two Week Low | 1.235 USD |
| Fifty-Two Week High Date | 02 Jan 2024 |
| Fifty-Two Week Low Date | 02 Oct 2023 |
| Price and Volume | |
| Current Price | 2.9 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 33.58% |
| Thirteen Week Relative Price Change | 11.51% |
| Twenty-Six Week Relative Price Change | -6.80% |
| Fifty-Two Week Relative Price Change | 3.78% |
| Year-to-Date Relative Price Change | -40.92% |
| Price Change | |
| One Day Price Change | 2.47% |
| Thirteen Week Price Change | 19.34% |
| Twenty-Six Week Price Change | 2.47% |
| Five Day Price Change | 6.62% |
| Fifty-Two Week Price Change | 30.04% |
| Year-to-Date Price Change | -30.04% |
| Month-to-Date Price Change | 35.51% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.35244 USD |
| Book Value Per Share (Most Recent Quarter) | 1.7193 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.35244 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.7193 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.18726 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.98208 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.00021 USD |
| Normalized (Last Fiscal Year) | -2.53518 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.98208 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.00021 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.98208 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.00021 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.76323 USD |
| Cash Per Share (Most Recent Quarter) | 2.05096 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.98134 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.00018 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.66596 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -6,030 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -7,896.43% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -8,240.67% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -7,900.37% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -17.73% |
| Tangible Book Value (5 Year) | 45.65% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 42.82% |
| EPS Change (Trailing Twelve Months) | 69.46% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -78,479,000 |
| Net Debt (Last Fiscal Year) | -70,643,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -43,753,000 |
| Free Cash Flow (Trailing Twelve Months) | -50,055,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -113.72% |
| Return on Assets (Trailing Twelve Months) | -67.81% |
| Return on Assets (5 Year) | -80.06% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -136.82% |
| Return on Equity (Trailing Twelve Months) | -80.54% |
| Return on Equity (5 Year) | -100.46% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -136.52% |
| Return on Investment (Trailing Twelve Months) | -80.19% |
| Return on Investment (5 Year) | -95.03% |